ID: ALA327715

Max Phase: Preclinical

Molecular Formula: C20H16N4O

Molecular Weight: 328.38

Molecule Type: Small molecule

Representations

Canonical SMILES:  N=C(N)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3O)nc2c1

Standard InChI:  InChI=1S/C20H16N4O/c21-19(22)13-9-10-16-17(11-13)24-20(23-16)15-8-4-7-14(18(15)25)12-5-2-1-3-6-12/h1-11,25H,(H3,21,22)(H,23,24)

Standard InChI Key:  LMGQGPVCSYOMNS-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 328.38

Molecular Weight (Monoisotopic): 328.1324

AlogP: 3.89

#Rotatable Bonds: 3

Polar Surface Area: 98.78

Molecular Species: BASE

HBA: 3

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 8.85

CX Basic pKa: 10.61

CX LogP: 3.16

CX LogD: 1.89

Aromatic Rings: 4

Heavy Atoms: 25

QED Weighted: 0.34

Np Likeness Score: -0.44

References

1. Verner E, Katz BA, Spencer JR, Allen D, Hataye J, Hruzewicz W, Hui HC, Kolesnikov A, Li Y, Luong C, Martelli A, Radika K, Rai R, She M, Shrader W, Sprengeler PA, Trapp S, Wang J, Young WB, Mackman RL..  (2001)  Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa.,  44  (17): [PMID:11495587] [10.1021/jm0100638]

2. Vijaykumar D, Sprengeler PA, Shaghafi M, Spencer JR, Katz BA, Yu C, Rai R, Young WB, Schultz B, Janc J..  (2006)  Discovery of novel hydroxy pyrazole based factor IXa inhibitor.,  16  (10): [PMID:16487703] [10.1016/j.bmcl.2006.01.123]

3. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

Source

Source(2):

• Scientific Literature
• AstraZeneca Deposited Data